Journal of Pharmacovigilance

Kaname Nakatani

Publications

• Research Article
  Polymorphisms of CYP3A5 Affect Serum Levels and Maintenance Doses of Tacrolimus in Myasthenia Gravis Patients
  Author(s): Naoki Kawaguchi, Kaname Nakatani, Akiyuki Uzawa, Yuko Nemoto, Keiichi Himuro and Satoshi KuwabaraNaoki Kawaguchi, Kaname Nakatani, Akiyuki Uzawa, Yuko Nemoto, Keiichi Himuro and Satoshi Kuwabara
  
  Objectives: To evaluate the influences of polymorphisms of cytochrome P450 (CYP) 3A5 (A6986G, CYP3A5*3) on serum levels of tacrolimus and cyclosporine (CyA) in patients with myasthenia gravis (MG). Methods: This study included 74 MG patients treated with tacrolimus (n=65) or CyA (n=22). Genomic DNA was extracted and amplified with specific primers, and CYP3A5 alleles were confirmed by direct sequencing of PCR products on an automated AB13100 DNA sequencer. We measured blood trough level (C0) of tacrolimus and CyA. Clinical disabilities were evaluated with the MG-ADL scale. Results: For tacrolimus C0, the CYP3A5*3/*3 genotype was associated with higher levels than the CYP3A5*1/*3 genotypes (7.1 ng/ml versus 2.9 ng/ml; P<0.0001) and CYP3A*1/*1 (7.1 ng/ml versus 1.3 ng/ml; P<0.0004). The improvement in the mean MG-ADL.. View More»
  DOI: 10.4172/2329-6887.1000258

  Abstract PDF